Elvitegravir (Vitekta)

Published October 15, 2012; Updated February 11, 2016
Susa Coffey, MD
http://hivinsite.ucsf.edu/InSite?page=ar-07-02
Selected Reference
6. Pozniak A, Markowitz M, Mills A, et al. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. Lancet Infect Dis. 2014 Jul;14(7):590-9.